Meeting
2013 ASCO Annual Meeting
PIKHER2: A phase Ib/II study evaluating safety and efficacy of oral BKM120 in combination with lapatinib in HER2-positive, PI3K-activated, trastuzumab-resistant advanced breast cancer.
Authors
Anthony Goncalves
Institut Paoli Calmettes, Marseille, France
Anthony Goncalves , Nicolas Isambert , Mario Campone , Veronique Dieras , Jean Marie Boher , Agnes Boyer-Chamard , Benjamin Esterni , Magali Provansal , Jean-Marc Extra , Patrice Viens
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer - HER2/ER
Track
Breast Cancer
Sub Track
HER2+
Clinical Trial Registration Number
NCT01589861
Citation
J Clin Oncol 31, 2013 (suppl; abstr TPS663)
DOI
10.1200/jco.2013.31.15_suppl.tps663
Abstract #
TPS663
Poster Bd #
16F
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Pyrotinib in combination with metronomic oral vinorelbine in patients with HER2-positive advanced breast cancer who had failed prior trastuzumab-based therapy: A single-center, single-arm, prospective phase 2 study.
First Author: Chunfang Hao
Poster
2014 ASCO Annual Meeting
Phase lb study of buparlisib (BKM120) plus either paclitaxel (PTX) in advanced solid tumors (aST) or PTX plus trastuzumab (TZ) in HER2+ breast cancer (BC).
First Author: Cristina Cruz Zambrano
Poster
2013 ASCO Annual Meeting
When less is better: Safety and efficacy of combination of trastuzumab and continuous low oral dose chemotherapy (HEX) as first-line therapy for HER2-positive advanced breast cancer (ABC)—First early results from a phase II trial on behalf of Gruppo Oncologico Italia Meridionale (GOIM).
First Author: Laura Orlando
Poster
2011 ASCO Annual Meeting
Oral PI3 kinase inhibitor BKM120 monotherapy in patients (pts) with advanced solid tumors: An update on safety and efficacy.
First Author: B. Grana